# DECISIÓN: COMPRAR Allstate (ALL)

**Fecha:** 2026-01-27
**Acción:** COMPRAR
**Ticker:** ALL (Allstate Corporation)
**Cantidad:** €400 (4% portfolio)
**Precio:** $197.65 (~€200 aprox)
**Shares:** 2

---

## Resumen Ejecutivo

Allstate es el #2 seguros hogar US (8.9%) y #4 auto (10.4%), cotizando a P/E 6.3x con ROE 37% y combined ratio 80% (Q3 2025). Oportunidad value excepcional: 51-72% más barata que peers con quality comparable. Turnaround 2022 pérdidas → 2025 $3.7B profit validado.

**Margen seguridad:** 21.4% (marginal <25%, pero exceptional execution justifica)

---

## Investment Committee - Checks

### Básicos
- [x] Thesis completa: thesis/research/ALL/thesis.md
- [⚠️] Margen >25%: 21% - APROBADO por consistency con Enel (21%) + superior ROE 37%
- [x] Moat: Narrow (brand + escala)
- [x] Riesgos aceptables: Competition, CAT losses, regulatory
- [x] Macro compatible: P&C insurance industry strong 2026

### Portfolio Structure V2.0
- [x] Sizing: 4% standard defensive (ajustado desde 5% por margen marginal)
- [x] Post-compra: 4% < 7% límite
- [x] Sectores: 5 sectores (Energy, Telecom, Utilities, Pharma, Insurance) < 25% cada uno
- [x] Geografías: 4 geografías (UK, Germany, Italy, US) < 35% cada una
- [x] Defensive: 15% post (Enel 6% + Pfizer 5% + ALL 4%) camino a 35-40%
- [x] Cyclical: 27% (Shell 15% + DTE 12%) camino a 45-50%
- [x] Cash: €5,800 (58%) > 5% mínimo
- [x] Posiciones: 5 de 16-20 target

---

## Razones de Compra

1. **Valuación excepcional:**
   - P/E 6.3x vs sector 12.9x = 51% descuento
   - 72% más barato que Admiral UK (P/E 22.8x, ROE 56%)
   - Fair value $236-240 → upside 21-46%

2. **Execution quality comprobada:**
   - Combined ratio 80% Q3 2025 vs industry 95% = +15pts outperformance
   - ROE 37% excelente (vs sector 15-20%)
   - Turnaround validado: 2022 -$1.4B → 2025 Q3 +$3.7B

3. **Diversificación necesaria:**
   - Primer insurance sector
   - US exposure adicional (tenía EU/UK heavy)
   - Defensive gap 11% → 15% (target 35-40%)

4. **Catalyst inmediato:**
   - Q4 2025 earnings: 5-feb-2026 (9 días)
   - Re-rating potential a P/E 10-12x sector average

---

## Riesgos Principales

1. **Margen 21% marginal (<25% standard)**
   - Mitigación: ROE 37%, combined ratio 80%, sizing conservador 4%
   - Precedente: Enel aprobado margen 21% con ROE inferior

2. **Competition P&C intensifying 2026**
   - Pricing momentum cooling (mid-90s combined ratio target vs 80% Q3)
   - Mitigación: Outperform industry combined ratio 99%

3. **CAT losses volatility (climate)**
   - Q1 2025: $2.2B, Q4 2025: $209M
   - Mitigación: Reinsurance, pricing adjustments, homeowners profitable

4. **Moat narrow (not wide like Admiral)**
   - P&C insurance commodity, pricing power limitado
   - Mitigación: Brand + escala suficientes (ROE 37%), sizing 4%

---

## Métricas Clave

| Métrica | Valor | Benchmark | Assessment |
|---------|-------|-----------|------------|
| P/E | 6.3x | Sector 12.9x | **Barato -51%** |
| ROE | 37% | Sector 15-20% | **Excelente** |
| Combined Ratio Q3 | 80.1% | Industry ~95% | **Best-in-class** |
| Net Income Q3 | $3.7B | +200% YoY | **Turnaround validado** |
| Book Value | $75-83/share | P/B 2.59x | Razonable |

---

## Balance Portfolio Post-Compra

**Posiciones:** 5 de 16-20 target

| Ticker | Valor | % Portfolio | Sector | Geografía | Tipo |
|--------|-------|-------------|--------|-----------|------|
| SHEL.L | €1,500 | 15% | Energy | UK | Cyclical |
| DTE.DE | €1,200 | 12% | Telecom | Germany | Cyclical |
| ENEL.MI | €600 | 6% | Utilities | Italy | Defensive |
| PFE | €500 | 5% | Pharma | US | Defensive |
| **ALL** | **€400** | **4%** | **Insurance** | **US** | **Defensive** |
| **Cash** | **€5,800** | **58%** | - | - | - |

**Composición:**
- Defensive: 15% (target 35-40%) → **GAP 20-25%**
- Cyclical: 27% (target 45-50%) → **GAP 18-23%**
- Sectores: 5 ✅
- Geografías: 4 ✅

---

## Seguimiento

**Evento Crítico Inmediato:**
- **5-feb-2026:** Allstate Q4 2025 earnings
  - Validar combined ratio Q4
  - Guidance 2026 (target mid-90s combined ratio)
  - CAT losses Q4
  - → Si miss → revisar thesis

**Métricas Monitorear:**
1. Combined ratio mantener <mid-90s
2. ROE >30%
3. Policies in force (PIF) growth
4. CAT losses quarterly
5. Pricing vs competition

**Revisar thesis si:**
- Combined ratio >100% (underwriting loss)
- ROE cae <25%
- Market share pierde >2pts por pricing
- CAT losses estructuralmente >$2B/quarter

---

## Próximos Pasos

Portfolio progreso hacia V2.0 structure:
- ✅ 5 posiciones (de 16-20)
- ⚠️ Defensive 15% (necesito +20-25% más)
- ⚠️ Cyclical 27% (necesito +18-23% más)

**Próxima acción:** Alternar a cyclical (ya añadí 3 defensive hoy: Enel, Pfizer, Allstate)

**Sectores cyclical pendientes explorar:**
- Energy adicional (TotalEnergies)
- Industrials (maquinaria, construcción)
- Materials (mining, commodities)
- Financials selectivos

**Continuar construcción gradual. Cash 58% es fortaleza mientras construyo.**
